



Origination 2/25/2021
 Last 3/31/2023
 Approved
 Effective 5/12/2023
 Next Review 4/30/2024

Lines Of Business All Lines of Business
 Area Payment Policy

COVID-19 Vaccine and Administration

Applicable Lines of Business:

- ✓ Commercial - Health Maintenance Organization (HMO), Preferred Provider Option (PPO) and Point of Service (POS)
- ✓ Medicare Advantage - SecureCare HMO (includes the Dual Eligible Special Needs Plan [DSNP]) and SecureChoice PPO
- ✓ Mountain Health Trust (MHT) including WV Medicaid (Temporary Assistance for Needy Families [TANF], Expansion [WV Health Bridge] and Supplemental Security Income [SSI] populations) and West Virginia Children's Health Insurance Program (WVCHIP)
- ✓ Self-Funded/Administrative Services Only (ASO)
- ✓ West Virginia Public Insurance Agency (WV PEIA)

Applicable Claim Type:

- Dental
- ✓ Facility
- ✓ Pharmacy
- ✓ Professional

Definitions:

Term	Definition
Bureau for Medical Services (BMS)	BMS is the designated single state agency responsible for the administration of the State of West Virginia's Medicaid program.
Centers for Medicare and Medicaid Services (CMS)	A federal agency that provides health coverage to more than 100 million people through Medicare, Medicaid, the Children's Health Insurance Program, and the Health Insurance Marketplace.
Children's Health Insurance	The Children's Health Insurance Program (CHIP) provides low-cost

Program (CHIP)	health coverage to children in families that earn too much money to qualify for Medicaid.
Claim Adjustment Reason Code (CARC)	A code used in medical billing to communicate a change or an adjustment in payment.
Coronavirus	A kind of common virus that causes an infection in the nose, sinuses, or upper throat.
COVID-19	Coronavirus disease 2019 (COVID-19) is an infectious respiratory illness caused by a virus called SARS-CoV-2.
Emergency Use Authorization (EUA)	An authority that allows the Food and Drug Administration (FDA) to help strengthen the nation's public health protections against chemical, biological, radiological and nuclear (CBRN) threats by facilitating the availability and use of medical counter measures (MCMs) needed during public health emergencies (PHE).
Federally Qualified Health Center (FQHC)	FQHCs are outpatient clinics that qualify for specific reimbursement systems under Medicare and Medicaid.
Medicare Administrative Contractor (MAC)	A Medicare Administrative Contractor (MAC) is a private health care insurer that has been awarded a geographic jurisdiction to process Medicare Part A and Part B (A/B) medical claims or Durable Medical Equipment (DME) claims for Medicare Fee-For-Service (FFS) beneficiaries. They are the primary operational contact between the Medicare FFS program and the health care providers enrolled in the program.
Public Health Emergency (PHE)	<p>A PHE may be declared by the Secretary of the Department of Health and Human Services (HHS) when it is determined that:</p> <ul style="list-style-type: none"> A. a disease or disorder presents a public health emergency (PHE); or B. that a public health emergency, including significant outbreaks of infectious disease or bioterrorist attacks, otherwise exists.
Rural Health Clinic (RHC)	RHCs are rurally located medical clinics providing healthcare services to patients in underserved areas.

Policy Purpose:

The purpose of this policy is to address general payment guidelines related to COVID-19 vaccines and vaccine administration as defined by The Health Plan (THP), the Centers for Medicare and Medicaid Services (CMS) and the Bureau for Medical Services (BMS) after the end of the Public Health Emergency on May 11, 2023.

Policy Description:

This policy is applicable to in-network and out-of-network providers and facilities.

Vaccines are covered under both the medical and pharmacy benefits, meaning a member may receive the COVID-19 vaccine in a provider's office or in a pharmacy.

The COVID-19 vaccine and administration codes listed below either have full FDA approval or are approved under the FDA's EUA.

Commercial, Self-Funded/ASO, and WV PEIA Reimbursement Guidelines:

COVID-19 Vaccines will be covered with no member cost sharing for vaccines administered by an in-network provider, and covered *with* member cost sharing for vaccines administered by an out-of-network provider.

The **administration** cost of the vaccine by a provider is billable to, and reimbursable by, The Health Plan (THP) for the Commercial, Self-Funded/ASO, and WV PEIA lines of business (LOB).

Medicare Advantage Reimbursement Guidelines:

COVID-19 Vaccines will be covered with no member cost sharing for vaccines administered by both in- and out-of-network providers.

The **administration** cost of the vaccine by a provider is billable to, and reimbursable by, The Health Plan (THP) for the Medicare Advantage LOB.

Mountain Health Trust (MHT) Reimbursement Guidelines:

As a result of the American Rescue Plan Act of 2021 (ARPA), states must provide Medicaid and CHIP coverage without cost sharing for COVID-19 vaccinations, testing, and treatments through the last day of the first calendar quarter that begins one year after the last day of the COVID-19 PHE. If the COVID-19 PHE ends as expected on May 11, 2023, this coverage requirement will end on September 30, 2024.

After that date, many Medicaid and CHIP enrollees will continue to have coverage for COVID19 vaccinations.

Instructions for COVID-19 vaccine administration to MHT members in a provider's office:

Providers will bill THP for the administration of the product-specific vaccine when the COVID-19 vaccines are administered in a **provider's office**.

Instructions for COVID-19 vaccine administration to MHT

members in a pharmacy:

Vaccines administered in a **pharmacy** will be covered under the member's FFS pharmacy benefit which is administered through the State of West Virginia's pharmacy vendor.

Providers are advised to bill FFS when the COVID-19 vaccines are administered at a pharmacy.

Pharmacy billing information is in the Bureau for Medical Services' (BMS) Provider Manual - Chapter 518 Pharmacy Services.

The Provider Manual may be accessed at: <https://dhhr.wv.gov/bms/Pages/Manuals.aspx>.

Billing information

When COVID-19 vaccine doses are provided by the government without charge, only bill for the vaccine administration. Don't include the vaccine code on the claim form.

Billing the vaccine code when it is free to the provider, along with the administration code, will result in a line item denial with billing error (BE) as the reason code on the claim form. The vaccine administration code will be paid.

The provider must bill the product-specific vaccine administration code.

Vaccine administration codes are reimbursable at the rate per the provider's contract.

If a provider sees a member for the sole purpose of administering a vaccine they may not routinely bill for an evaluation and management (E&M) visit.

However, the provider can bill for an E&M service furnished on the same day as a vaccine when the provider performs a medically necessary, and significant, separately identifiable E&M visit in addition to the vaccine administration.

Member cost-sharing will not apply if a provider performs a medically necessary E&M service on a patient that has come into the office for the primary purpose of getting a COVID-19 vaccine.

Providers furnishing these services on the same day should add modifier "25" to the E&M code to identify it as a medically necessary E&M service furnished on the same day that another service is furnished by the same physician or other supplier.

MHT Billing/Reimbursement for Federally Qualified Health Centers (FQHCs) and Rural Health Clinics (RHCs):

The provider will receive reimbursement for the vaccine administration only when the vaccine is free of charge to the provider.

When administering the vaccine, with no other service performed on the same date of service (DOS), bill the product-specific vaccine administration code from the table below on a HCFA 1500 professional claim form.

When performing any other encounter-related service on the same date of service as the vaccine administration, the provider will receive the applicable encounter rate plus the vaccine administration reimbursement.

To receive the encounter rate in addition to the vaccine administration on the same DOS, the provider is advised to bill:

- The encounter-related service on a hospital UB04 claim form
- The product-specific vaccine administration code on a HCFA 1500 professional claim form
- Do not include the vaccine code on the claim when the vaccine is free to the provider

CPT codes for approved coronavirus vaccines:

Note: Approval of a vaccine and its related codes by CMS and the FDA does not guarantee coverage by WV Medicaid/WVCHIP. Providers should contact THP Customer Service to confirm coverage of codes.

Category 1 CPT Codes	Labeler Name	FDA EUA Approval Date	Description
91300	Pfizer	12.11.2020	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/ 0.3mL dosage, diluent reconstituted, for intramuscular use.
91301	Moderna	12.18.2020	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/ 0.5mL dosage, for intramuscular use.
91303	Janssen (Johnson & Johnson)	02.27.2021	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use.
91304	Novavax	07.13.2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use
91305	Pfizer	01.03.2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91306	Moderna	10.20.2021	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine,

			mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage.
91307	Pfizer	10.29.2021	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use.
91308	Pfizer	06.17.2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (pediatric vaccine)
91309	Moderna	03.29.2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use (Booster)
91311	Moderna	06.17.2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
91312	Pfizer	8/31/2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Aged 12 years and older) (Gray Cap)
91313	Pfizer	8/31/2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use (Aged 12 years and older) (Dark Blue Cap with gray border)
91314	Moderna	10/12/2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use (Aged 6 years through 11 years) (Dark Blue Cap with gray border)
91315	Pfizer	10/12/2022	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Aged 5 years through 11 years) (Orange Cap)
91316	Moderna	12/8/2022	Moderna COVID-19 Vaccine, Bivalent (Aged 6 months

			through 5 years) (Dark Pink Cap and label with a yellow box) Administration – Booster Dose
91317	Pfizer	12/8/2022	Pfizer-BioNTech COVID-19 Vaccine, Bivalent Product (Aged 6 months through 4 years) (Maroon Cap)

The following CPT code(s) do not have FDA/CMS/BMS approval and are not approved coronavirus vaccine(s):

91302	Astra Zeneca	TBD	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use
-------	--------------	-----	---

Approved coronavirus product-specific vaccine administration codes:

Note: Approval of a vaccine and its related codes by CMS and the FDA does not guarantee coverage by WV Medicaid/WVCHIP. Providers should contact THP Customer Service to confirm coverage of codes.

Vaccine Administration Codes	Labeler Name	Description
0001A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose.
0002A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose.
0003A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose.
0004A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose
0011A	Moderna	Immunization administration by intramuscular injection of

		severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose.
0012A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose.
0013A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose
0031A	Janssen (Johnson & Johnson)	Immunization administration by intramuscular injection of SARS-CoV-2 (COVID-19) vaccine, DNA, spike protein, Ad26 vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, single dose.
0034A	Janssen (Johnson & Johnson)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; booster dose.
0041A	Novavax	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose
0042A	Novavax	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose
0044A	Novavax	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage Booster
0051A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose
0052A	Pfizer	Immunization administration by intramuscular injection of

		severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose
0053A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose
0054A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose
0064A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose.
0071A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose.
0072A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose.
0073A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose
0074A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose
0081A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
0082A	Pfizer	Immunization administration by intramuscular injection of

		severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
0083A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose
0091A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years
0092A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years
0093A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years
0094A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose
0111A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose
0112A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose
0113A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose

0124A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose
0134A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose (Aged 12 years and older) (Dark Blue Cap with gray border)
0144A	Moderna	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose
0154A	Pfizer	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose
0164A	Moderna	Moderna COVID-19 Vaccine, Bivalent (Aged 6 months through 5 years) (Dark Pink Cap and label with a yellow box) Administration – Booster Dose
0173A	Pfizer	Pfizer-BioNTech Covid-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) Administration - Third dose
M0201	N/A	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home

The following CPT codes do not have FDA/CMS/BMS approval and are not approved coronavirus product-specific vaccine administration codes:

0021A	Astra Zeneca	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5×10^{10} viral particles/0.5mL dosage; first dose.
0022A	Astra Zeneca	Immunization administration by intramuscular injection of

		severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage; second dose
--	--	---

Additional Billing Information and Guidelines:

More billing information may be found in The Health Plan's Provider Manual located at healthplan.org "For Providers," "Resources."

Review/Revision History:

	Date	Action
Policy Issue Date	3/12/2021	
Date Revised	09/13/2021	Removed "Under Emergency Use Authorization" from the policy's title.
	09/13/2021	Added the term "Public Health Emergency (PHE)" and definition under the "Definitions" section.
	09/13/2021	Removed "under an emergency use authorization (EUA) by the US Food and Drug Administration (FDA)" from the first sentence under "Policy Purpose."
	09/13/2021	Changed the first sentence under "Policy Description" to "This policy became effective on March 12, 2021 and was revised September 13, 2021."
	09/13/2021	Added the statement "either have full FDA approval or" under the "Commercial and WV PEIA", the "Medicare Advantage", the MHT and the ASO/Self-Funded Reimbursement Guidelines sections.
	09/13/2021	Changed the word "beneficiaries" to "members" under the Medicare Advantage Reimbursement Guidelines section.
	09/13/2021	Added the sentence "The Provider Manual may be accessed at: https://dhhr.wv.gov/bms/Pages/Manuals.aspx " under the subheading "Instructions for COVID-19 vaccine administration to MHT members in a pharmacy."
	09/13/2021	Added "Full FDA approval granted 08.23.21" under CPT code 91300 in the "Billing" subsection "CPT codes for approved coronavirus vaccines."
	09/13/2021	Added vaccine administration code 0003A and the description for the third dose Pfizer vaccine under "Approved coronavirus product-specific vaccine administration codes" table.
	09/13/2021	Added vaccine administration code 0013A and the description for the third dose Moderna vaccine under "Approved coronavirus product-specific vaccine administration codes" table.

	11.22.2021	Changed revised date to November 22, 2021 under "Policy Description."
	11.22.2021	Added vaccine codes 91306 and 91307 and their descriptions to the table titled "CPT codes for approved coronavirus vaccines."
	11.22.2021	Added vaccine administration codes 0034A, 0064A, 0071A and 0072A and their descriptions under the "Approved coronavirus product-specific vaccine administration codes" table.
	12.6.21	<p>Removed the following statements from the "Medicare Advantage Reimbursement Guidelines" section:</p> <ul style="list-style-type: none"> • Providers are advised not to bill THP for the vaccine or the administration of the vaccine to THP Medicare Advantage members. • For Calendar Years (CYs) 2020 and 2021, Medicare payment for the COVID-19 vaccine and its administration for members enrolled in Medicare Advantage plans will be made through the original fee-for-service (FFS) Medicare program. • Providers are advised to submit claims for administering the COVID-19 vaccine to the Centers for Medicare and Medicaid Services (CMS) Medicare Administrative Contractor (MAC) using product-specific administration codes for each vaccine approved. • Medicare Advantage claims erroneously submitted to THP for reimbursement will deny FS (fee-for-service). • Providers may also see the Claim Adjustment Reason Code (CARC) listed below, when applicable, on their payment voucher. • Reason code: • 109 - Claim/service not covered by this payer/contractor. You must send the claim/service to the correct payer/contractor.
	12.6.21	<p>Added the statements below to the "Medicare Advantage Reimbursement Guidelines" section:</p> <ul style="list-style-type: none"> • Effective January 1, 2022, The administration cost of the vaccine by a provider is billable to, and reimbursable by, The Health Plan (THP) for the Medicare Advantage LOB. • See the "Review/Revision History" section of the policy under revised date 12.6.21 for information on billing vaccine administration to Medicare Advantage members prior to January 1, 2022.
Annual Review	July 11, 2022	Added CPT codes 91304, 91305, 91308, 91311, and 91309. Added vaccine administration codes 0004A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, and 0113A. Reviewed and updated

		references.
Revision	November 23, 2022	Added CPT codes 91312, 91313, 91314, and 91315. Added vaccine administration codes 0044A, 0124A, 0134A, 0144A, and 0154A. Updated description for 0022A. Updated references.
Annual Review	March 7, 2023	Updated policy to include guidelines for vaccines at the end of the PHE: Combined the commercial, self-funded/ASO, and WV PEIA sections. No cost sharing for in-network, and with cost sharing for out-of-network providers for commercial, self-funded/ASO, and WV PEIA. No cost sharing both in- and out-of-network for MA members. MHT members will continue to receive vaccines with no cost sharing through September 30, 2024 per ARPA. Moved "The COVID-19 vaccine and administration codes listed below either have full FDA approval or are approved under the FDA's EUA" to the Policy Description section and removed this statement from each individual LOB section. Updated references and formatting. Added codes 91316, 91317, 0164A, 0173A, and M0201.

References and Research Materials:

Centers for Medicare and Medicaid Services (CMS). COVID-19 Vaccines and Monoclonal Antibodies. Last modified February 2, 2023, accessed March 7, 2023. Available at: <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies>

FDA Approves First COVID-19 Vaccine. U.S. Food and Drug Administration. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine>

Toolkit on COVID-19 Vaccine: Health Insurance Issuers and Medicare Advantage Plans. Centers for Medicare and Medicaid Services. Available at: <https://www.cms.gov/files/document/COVID-19-toolkit-issuers-MA-plans.pdf>

Centers for Medicare and Medicaid Services (CMS). MLN Connects 2022-07-14-MLNC. July 14, 2022. Accessed July 14, 2022. https://www.cms.gov/outreach-and-education/outreachffsprovpartprogprovider-partnership-email-archive/2022-07-14-mlnc#_Toc108597545

United States Food and Drug Administration (FDA). Coronavirus Disease 2019 (COVID-19) EUA: Vaccines. Accessed July 13, 2022. <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#vaccines>

Centers for Medicare and Medicaid (CMS). What do I need to know? CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency. Published February 27, 2023. Accessed February 28, 2023.

United States Food and Drug Administration. FAQs: What happens to EUAs when a public health emergency ends? Updated January 31, 2023. Accessed February 28, 2023.

United States Department of Health and Human Services. Fact Sheet: COVID-19 Public Health Emergency Transition Roadmap. Published February 9, 2023. Accessed February 28, 2023.

Disclaimer:

This policy is intended to provide a general reference regarding billing, coding and documentation guidelines. Coding methodology, regulatory requirements, industry standard claims editing logic, benefit design and other factors are considered in developing payment policies. This policy is intended to serve as a guideline only and does not constitute medical advice, any guarantee of payment, plan pre-authorization, an explanation of benefits, or a contract. This policy does not govern whether a specific procedure is covered under any specific member plan or policy, nor is it intended to address every claim situation. The determination that any service, procedure, item, etc., is covered under a member's benefit plan shall not be construed as a determination that a provider will be reimbursed for services provided. Individual claims may be affected by other factors, including but not necessarily limited to state and federal laws and regulations, legislative mandates, provider contract terms, and THP's professional judgment.

Reimbursement for any services shall be subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification and utilization management guidelines.

Unless otherwise noted within the policy, THP's policies apply to both participating and non-participating providers and facilities. THP reserves the right to review and revise these policies periodically as it deems necessary in its discretion, and it is subject to change or termination at any time by THP. THP has full and final discretionary authority for its interpretation and application. Accordingly, THP may use reasonable discretion in interpreting and applying this policy to health care services provided in any particular case.

No part of this policy may be reproduced, stored in a retrieval system or transmitted, in any shape or form or by any means, whether electronic, mechanical, photocopying or otherwise, without express written permission from THP. When printed, this version becomes uncontrolled. For the most current information, refer to the following website: healthplan.org.

All Revision Dates

3/31/2023, 1/10/2023, 9/13/2022, 12/30/2021, 9/24/2021, 3/9/2021, 2/18/2021

Attachments

[COVID-19-toolkit-issuers-MA-plans.pdf](#)

[FDA Approves First COVID-19 Vaccine News Release.pdf](#)

[medicare-part-b-drug-average-sales.pdf](#)